PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 4, 2026Endocrine Related Cancer0 citationsOpen Access

PRRT for well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

View Full Paper
VCVirginia CorbettGGGarima GuptaACAman Chauhan

Key Points

  • To evaluate the sequencing of peptide receptor radionuclide therapy (PRRT) to optimize treatment for GEP-NETs.
  • Reviewed current literature on PRRT and its application in GEP-NET management.
  • Assessed patient-specific factors for tailoring treatment plans.
  • Emphasized a multidisciplinary approach in decision-making.
  • Found that optimized sequencing may lead to improved patient outcomes.
  • Highlighted the importance of personalized treatment approaches in GEP-NET care.

Abstract

Optimizing its sequencing with other treatments requires further research but offers potential for improved outcomes. A personalized, multidisciplinary approach is essential for maximizing PRRT's benefits in NET management. This review article summarizes current evidence and describes patient specific circumstances, enabling treating provider to make informed PRRT sequencing decisions.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Corbett et al. (2026) studied this question.

synapsesocial.com/papers/69a7cd7ed48f933b5eed9e52https://doi.org/10.1530/erc-25-0495
Ask AI
Helpful
Bookmark
Share
View Full Paper